- Home
- AVTX vs CII Comparison
AVTX vs CII Comparison
Compare AVTX & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | CII |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.7M | 1.0B |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AVTX | CII |
|---|---|---|
| Price | $19.51 | $23.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $40.57 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 75.8K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $6.51 | $20.43 |
| 52 Week High | $24.27 | $26.17 |
Technical Indicators
Market Signals| Indicator | AVTX | CII |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 35.52 |
| Support Level | $17.32 | $23.04 |
| Resistance Level | $20.68 | $24.45 |
| Average True Range (ATR) | 1.18 | 0.43 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 67.70 | 12.34 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.